<DOC>
	<DOC>NCT01427751</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).</brief_summary>
	<brief_title>Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis of branch retinal vein occlusion in at least one eye Visual acuity between 20/400 to 20/40 Active eye infection Ocular hypertension which is not controlled on monotherapy (one medication) Anticipated need for eye surgery during the study Cataract surgery in either eye within 3 months Eye surgery including laser of any type within 6 months AntiVEGF treatment in either eye (eg, Lucentis®) within 3 months or systemic antiVEGF treatment (eg, Avastin) within 6 months Use of ocular steroids within 3 months Use of steroids (except for inhaled or intranasal) within 1 month or anticipated use during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>